The tumor microenviroment and immune barrier are known to modulate malignant disease progression. We have recently identified Galectin-1 as a key player in a novel stromal regulatory reaction driving immune evasion in pancreatic tumors in vivo. These results suggest that Galectin-1 inhibition represents a potential therapeutic strategy for one of the most deadly types of cancer.
No takes yet. Share an insight, caveat, or question.
Martínez‐Bosch et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: